Our results demonstrate a novel MALAT1/miR-1-3p/BRF2/LKB1/AMPK regulatory axis in HCC, which may provide new molecular therapeutic targets for HCC in the future. This evidence concerns the gene PRKAA2 and hepatocellular carcinoma.